Dengue Fever Market

Market Overview:

The 7 major dengue fever markets are expected to exhibit a CAGR of 10.21% during 2024-2034.

The dengue fever market has been comprehensively analyzed in IMARC's new report titled "Dengue Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dengue fever refers to a mosquito-borne tropical illness caused by the dengue virus (DENV). The virus is passed to humans through the bites of infected female mosquitoes. After the incubation period of 4–10 days, the patient may experience a range of symptoms. Some of the characteristic indications of this condition include a high fever, severe headache, muscle and joint pains, pain behind the eyes, nausea, vomiting, swollen glands, a rash, etc. In rare cases, the disease can develop into serious forms, like dengue shock syndrome, which can cause bleeding, blood plasma leakage, and a low platelet count. The diagnosis of this ailment is typically made through a combination of the patient's clinical symptoms, travel history, and laboratory tests. Molecular analysis, including reverse transcription polymerase chain reaction (RT-PCR), is also utilized to detect the presence of the virus's genetic material in a person's blood. This investigation can help to confirm a diagnosis within the first week of illness. Additionally, the healthcare provider may perform a complete blood count to evaluate the levels of different blood cells, such as platelets, that might indicate the disease.

The escalating cases of viral infections, which cause microorganisms to enter the bloodstream and replicate in the human body, are primarily driving the dengue fever market. Additionally, the rising prevalence of poor waste management and inadequate sanitation that can lead to an increase in mosquito breeding sites, thereby facilitating the spread of the virus, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective analgesics, such as acetaminophen and tramadol, since they help to manage symptoms of the ailment, including fever, headache, and muscle and joint pain, is further bolstering the market growth. Apart from this, the inflating application of intravenous fluids to treat patients who cannot tolerate oral intake is acting as another significant growth-inducing factor. This therapy prevents dehydration and supports vital organ function by restoring fluid balance and maintaining electrolyte levels during the course of the illness. Additionally, the emerging popularity of mosquito repellent topical creams that contain a higher concentration of N, N-diethyl-meta-toluamide, or picaridin to provide longer-lasting protection against the infection is expected to drive the dengue fever market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the dengue fever market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for dengue fever and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dengue fever market in any manner.

Recent Developments:

• In June 2024, Island Pharmaceuticals reported progress in their trial program for dengue fever treatment, stating that new data could lead to more efficient Phase II clinical investigations by determining an optimal single dose for the ISLA-101 medication.
• In October 2023, Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) reported encouraging results from a Phase IIa human challenge study testing JNJ-1802, a first-in-class oral antiviral in development for dengue prevention. The results demonstrated that the chemical exhibited antiviral activity against dengue (DENV-3) in humans when compared to a placebo and that it is safe and well-tolerated.

Key Highlights:

• Dengue Fever incidence has increased 30-fold during the last 50 years, with geographic extension to new nations and, in the current decade, from urban to rural settings.
• An estimated 50 million dengue infections occur each year, and approximately 2.5 billion people reside in dengue-endemic areas.
• Approximately 1.8 billion (more than 70%) of the world's population at risk for dengue lives in member states of the WHO South-East Asia and Western Pacific Regions, which account for almost 75% of the current global dengue burden.
• Dengue epidemics follow a seasonal pattern, with peak incidence occurring during and after the warm and rainy seasons. An increase in mosquito population is one factor that contributes to the disease's epidemic spread.
• Dengue is most common in children in endemic locations (mostly Southeast Asia), with dengue hemorrhagic fever being the leading cause of mortality, with a case fatality rate of 3 to 10%.

Drugs:

Dengvaxia is a tetravalent live-attenuated dengue vaccine. It was created using recombinant DNA technology and replaces numerous genetic regions in a yellow fever vaccine virus genome with the homologous sequences of the four dengue virus serotypes, DENV-1-4.

V181 is an experimental live, attenuated, quadrivalent dengue vaccine. In the phase I double-blind, placebo-controlled research, the safety, tolerability, and immunogenicity of V181 in baseline flavivirus-naïve and flavivirus-experienced healthy people were investigated in two formulations: TV003 and TV005.

JNJ-1802, a novel dengue inhibitor being developed by Janssen Pharmaceutica, is one of the most advanced candidate dengue antivirals and has recently been proven to drastically reduce viral load in preclinical animal experiments.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dengue fever market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dengue fever market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current dengue fever marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the dengue fever market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the dengue fever market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the dengue fever market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of dengue fever across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dengue fever by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dengue fever by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with dengue fever across the seven major markets?
• What is the size of the dengue fever patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of dengue fever?
• What will be the growth rate of patients across the seven major markets?
   

Dengue Fever: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for dengue fever drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dengue fever market?
• What are the key regulatory events related to the dengue fever market?
• What is the structure of clinical trial landscape by status related to the dengue fever market?
• What is the structure of clinical trial landscape by phase related to the dengue fever market?
• What is the structure of clinical trial landscape by route of administration related to the dengue fever market?